Evommune Announces Initiation of Phase 2 Trial of MRGPRX2 Antagonist, EVO756, for Chronic Spontaneous Urticaria.

Read More

About Us
Our Science
Our Pipeline
Join Us
- Our Culture
- Job Openings
Newsroom
- Press Releases

Select Page

back to management

Sectoral_Asset_Management

15 of 17

15 of 17

About Us

Overview
Leadership
Collaborating
Contact

Our Science

Approach
Disease Focus
Publications & Posters

Our Pipeline

Development Pipeline
MRGPRX2 Antagonist
IL-18 Fusion Protein
Clinical Trials

Join Us

Our Culture
Job Openings

Newsroom

Press Releases

© 2025 Evommune, Inc.

Privacy Policy
Terms of Use

Website by 22 Fillmore